Different profile of gene expression of cytokines in peripheral blood mononuclear cells of transplant recipients treated with m-TOR inhibitor and calcineurin inhibitor

Transplant Immunology

Volumn 20, Issue 3, 2009, Pages 139-142

  Niemczyk, Mariusz ^a   Zegarska, Jolanta ^a   Pawłowska, Monika ^a   Wyzgał, Janusz ^a   Ciszek, Michał ^a   Paczek, Leszek ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Calcineurin inhibitors; Cytokines; Kidney transplant; Liver transplant; Peripheral blood mononuclear cells; Sirolimus

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; RAPAMYCIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL TRANSPLANTATION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SUBSTITUTION; GENE EXPRESSION; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; MONOTHERAPY; NEPHROTOXICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TH1 CELL; TH2 CELL; VIRUS INFECTION;

CASE-CONTROL STUDIES; CYCLOSPORINE; CYTOKINES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LEUKOCYTES, MONONUCLEAR; LIVER TRANSPLANTATION; SIROLIMUS; TACROLIMUS; TRANSPLANTATION;

EID: 57549086091     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2008.09.005     Document Type: Article

References (32)

1. Edwards E.B., Bennett L.E., and Cecka J.M. Effect of HLA matching on the relative risk of mortality for kidney recipients: a comparison of the mortality risk after transplant to the mortality risk of remaining on the waiting list. Transplantation 64 (1997) 1274
2. Yates P.J., and Nicholson M.L. The aetiology and pathogenesis of chronic allograft nephropathy. Transplant Immunol 16 (2006) 148
3. Buell J.F., Gross T.G., and Woodle E.S. Malignancy after transplantation. Transplantation 80 2 Suppl (2005) S254
4. Aroldi A., Lampertico P., Montagnino G., Passerini P., Villa M., Campise M.R., et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 79 (2005) 1132
5. Backman L., Gibbs J., Levy M., McMillan R., Holman M., Husberg B., et al. Causes of late graft loss after liver transplantation. Transplantation 55 (1993) 1078
6. Machaliński B., Honczarenko M., Gontarewicz A., and Ratajczak M.A. Isolation of mononuclear cells from bone marrow, peripheral, and cord blood employing Ficoll-Paque (Pharmacia) or Gradisol L (Polfa). Comparison of both methods. Pol Arch Med Wew 99 (1998) 15
7. Chomczyński P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162 (1987) 156
8. Shirwan H. Chronic allograft rejection: do the Th2 cells preferentially induced by indirect alloantigen recognition play a dominant role?. Transplantation 68 (1999) 715
9. Oberbauer R., Segoloni G., Campistol J.M., Kreis H., Mota A., Lawen J., et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transplant Int 18 (2005) 22
10. Groth C.G., Backman L., Morales J.M., Calne R., Kreis H., Lang P., et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 67 (1999) 1036
11. Kreis H., Cisterne J.M., Land W., Wramner L., Squifflet J.P., Abramowicz D., et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69 (2000) 1252
12. Dominguez J., Mahalati K., Kiberd B., McAlister V.C., and MacDonald A.S. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 70 (2000) 1244
13. Renders L., Steinbach R., Valerius T., Schocklmann H.O., and Kunzendorf U. Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggest pharmacokinetic interaction of both immunosuppressive drugs. Kidney Blood Press Res 27 (2004) 181
14. Wyzgał J., Pa{ogonek}czek L., Senatorski G., Zygier D., Rowiński W., Szmidt J., et al. Sirolimus rescue treatment in calcineurin-inhibitor nephrotoxicity after kidney transplantation. Transplant Proc 34 (2002) 3185
15. Johnson R.W.G., Kreis H., Oberbauer R., Brattstrom C., Claeson K., and Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72 (2001) 777
16. Thaunat O., Beaumont C., Chatenoud L., Lechaton S., Mamzer-Bruneel M.F., Varet B., et al. Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation 80 (2005) 1212
17. Morelon E., and Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 35 Suppl (2003) 52S
18. Mosmann T.R., and Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17 (1996) 138
19. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8 (2002) 128
20. Law B.K. Rapamycin: an anti-cancer immunosuppressant?. Crit Rev Oncol Hematol 56 (2005) 47
21. Campistol J.M., Eris J., Oberbauer R., Friend P., Hutchison B., Morales J.M., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17 (2006) 581
22. Campistol J.M., Gutierrez-Dalmau A., and Torregrosa J.V. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 77 (2004) 760
23. Kahan B.D., Yakupoglu Y.K., Schoenberg L., Knight R.J., Katz S.M., Lai D., et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 80 (2005) 749
24. Kauffman H.M., Cherikh W.S., Cheng Y., Hanto D.W., and Kahan B.D. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with reduced incidence of de novo malignancies. Transplantation 80 (2005) 883
25. Stallone G., Schena A., Infante B., Di Paolo S., Loverre A., Maggio G., et al. Sirolimus for Kaposis's sarcoma in renal-transplant recipients. N Engl J Med 352 (2005) 1317
26. Sanchez A., Nagy P., and Thorgeirsson S.S. STAT-3 activity in chemically-induced hepatocellular carcinoma. Eur J Cancer 39 (2003) 2093
27. Fang P., Hwa V., and Rosenfeld R.G. Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway. Exp Cell Res 312 (2006) 1229
28. Huang Y., Horvath C.M., and Waxman S. Regrowth of 5-fluorouracil-treated human colon cancer cells is prevented by the combination of interferon γ, indomethacin, and phenylbutyrate. Cancer Res 60 (2000) 3200
29. Inamura K., Matsuzaki Y., Uematsu N., Honda A., Tanaka N., and Uchida K. Rapid inhibition of MAPK signaling and anti-proliferation effect via JAK/STAT signaling by interferon-alpha in hepatocellular carcinoma cell lines. Biochim Biophys Acta 1745 (2005) 401
30. Samonakis D.N., Cholongitas E., Triantos C.K., Griffiths P., Dhillon A.P., Thalheimer U., et al. Sustained, spontaneous disappearance of serum HCV-RNA under immunosuppression after liver transplantation for HCV cirrhosis. J Hepatol 43 (2005) 1091
31. Dharancy S., Catteau B., Mortier L., Boleslawski E., Declerck N., Canva V., et al. Conversion to sirolimus: a useful strategy for recalcitrant cutaneous viral warts in liver transplant recipient. Liver Transpl 12 (2006) 1883
32. Neff G.W., Ruiz P., Madariaga J.R., Nishida S., Montalbano M., Meyer D., et al. Sirolimus-associated hepatotoxicity in liver transplantation. Ann Pharmacother 38 (2004) 1593